| Anebulo Pharmaceuticals is a clinical-stage biotechnology company developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Co.'s primary product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, to address the unmet medical need for a specific antidote for ACI. ANEB-001 is an orally bioavailable absorbed treatment. Co.'s proprietary position in the treatment of ACI is protected by an issued patent and rights to a patent application covering various methods of use of the compound and delivery systems. The ANEB average annual return since 2021 is shown above.
The Average Annual Return on the ANEB average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ANEB average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ANEB average annual return calculation with any dividends reinvested as applicable (on ex-dates).